Children's Hospital of Atlanta
Atlanta, GA
Accepting patients
CARE Study
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results